Khavinson Bioregulators: The Research Programme, the Mechanism and the Evidence

Khavinson bioregulators are a class of synthetic di-, tri- and tetrapeptides developed by Professor Vladimir Khavinson (1946-2024) and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology over more than four decades of research. The central hypothesis is that each organ and tissue produces specific short peptides that help regulate its own gene expression, and that supplementing those peptides externally can restore expression patterns that decline with age.

This is a fundamentally different proposed mechanism from most peptide pharmacology. Receptor-binding peptides such as GLP-1 agonists or GH secretagogues act at cell-surface receptors and trigger intracellular signalling cascades. Bioregulators are proposed to bypass surface receptors entirely, penetrating cell membranes and entering the nucleus to interact with chromatin and DNA directly.

The programme produced two generations of compounds. The first generation, known as Cytomaxes or Cytamins, are peptide fractions extracted from animal organs (thymus, pineal gland, brain cortex, retina, prostate and others). The second generation, known as Cytogens, are fully synthetic short peptides whose sequences were identified as the active components within those earlier extracts. Most of the bioregulators discussed in longevity research today are Cytogens.

The bottom line: Khavinson bioregulators represent a distinct category of peptide research based on the hypothesis that ultra-short peptides can modulate gene expression at the epigenetic level in a tissue-specific manner.

The systematic study of peptide bioregulators began in the early 1970s at the Military Medical Academy named after S.M. Kirov in what was then Leningrad. The original work was partly motivated by Soviet military and space interests, with scientists seeking methods to protect personnel from the accelerated ageing effects of extreme stress, radiation and demanding operational environments.

The early methodology involved extracting peptide fractions from specific calf organs, then testing those extracts in cell culture, animal models and eventually human clinical programmes. Over time the research evolved from crude tissue extracts toward identification and synthesis of the individual short peptide sequences that appeared to account for the observed biological activity.

Khavinson’s Publication Record

By the time of Khavinson’s death on 6 January 2024 at the age of 77, the programme had produced over 775 peer-reviewed publications across journals including the Bulletin of Experimental Biology and Medicine, Biogerontology, Advances in Gerontology and Neuroendocrinology Letters, along with 196 patents (90 international). Two key monographs anchor the field: Peptides and Ageing (Neuroendocrinology Letters, 2002) and Gerontological Aspects of Genome Peptide Regulation (Karger AG, 2005). A landmark review by Anisimov and Khavinson in Biogerontology (2010) consolidated the programme’s first three decades of experimental data into a single reference framework.

Six Registered Pharmaceuticals

Six peptide-based preparations from the programme received authorisation from the Russian Ministry of Health for clinical use. These were originally developed for the military medical service and later extended to civilian healthcare in Russia and CIS countries:

• Thymalin – thymus extract, cellular immunity regulator
• Epithalamin – pineal gland extract, endocrine system regulator and melatonin restorer
• Cortexin – brain cortex extract, cerebral function regulator (manufactured by GEROPHARM)
• Prostatilen (also branded Samprost/Vitaprost) – prostate gland extract, urogenital function regulator
• Retinalamin – retina extract, vision function restorer
• Thymogen – synthetic dipeptide (Glu-Trp), immune function regulator, first extracted from thymalin then synthesised from amino acids

None of these six preparations have received regulatory approval from the FDA, EMA or MHRA. Outside Russia and the former Soviet states, they remain unapproved research compounds.

The bottom line: The Khavinson programme produced six registered pharmaceuticals in Russia and hundreds of peer-reviewed publications, but regulatory recognition has not extended beyond Russia and CIS countries.

The proposed mechanism rests on the interaction between short peptides and chromatin, the protein-DNA complex that governs gene accessibility. In aged cells, chromatin tends toward a condensed (heterochromatin) state in which gene promoters are silenced. Khavinson’s group published data indicating that short peptides with specific amino acid compositions can bind to histone proteins and to specific DNA sequences in the major groove, altering chromatin conformation toward a more open (euchromatin) state and increasing transcriptional activity at targeted gene loci.

The tissue specificity claim is central to the framework. Each bioregulator’s amino acid sequence is proposed to be complementary to the DNA regulatory sequences active in its target tissue. A cardiac peptide (cardiogen) would preferentially affect heart cells, while a thymic peptide (vilon) would preferentially affect immune cells, because each peptide recognises specific promoter motifs through electrostatic and steric complementarity.

This mechanism is distinct from HDAC inhibitors (drugs that broadly prevent histone deacetylation). The bioregulators are proposed to act with sequence specificity rather than global epigenetic effects. It is also distinct from transcription-factor-based gene therapy, as the peptides do not themselves function as transcription factors but are hypothesised to alter the accessibility of DNA to the cell’s existing transcriptional machinery.

The two compounds in PeptideGuider’s longevity cluster that operate through this proposed mechanism are epitalon (the synthetic AEDG tetrapeptide targeting the pineal gland and telomerase) and pinealon (the synthetic EDR tripeptide targeting neuroprotection via DNA-promoter interaction). Each compound’s specific mechanism and evidence base is covered in its dedicated guide.

The bottom line: The proposed mechanism involves short peptides penetrating the nucleus and interacting with specific DNA sequences to restore age-related gene expression decline, but this mechanism remains a hypothesis under investigation rather than established pharmacology.

Three lines of experimental work provide the most direct evidence for the proposed chromatin-interaction mechanism, and they are worth examining individually because each addresses a different aspect of the claim.

The Lezhava Chromatin Reactivation Studies (Tbilisi)

Between 2002 and 2006, Teimuraz Lezhava at Tbilisi State University in Georgia (not the St Petersburg Institute) collaborated with Khavinson on a series of chromatin studies in cultured lymphocytes from elderly donors aged 75-88. These studies are notable because they were conducted at a different institution and provide one of the few semi-independent tests of the chromatin mechanism.

The 2004 Biogerontology study (Lezhava et al., PMID 15105581) tested vilon (KE dipeptide) on aged human lymphocytes and reported four specific findings: vilon induced unrolling (deheterochromatinisation) of total heterochromatin; it activated synthetic processes by reactivating ribosomal genes in nucleolus organiser regions; it released genes repressed by age-related condensation of euchromatic regions; but it did not induce decondensation of pericentromeric structural heterochromatin. That last finding is significant because it suggests the peptide’s effect is selective, not a blanket loosening of all chromatin.

A follow-up study (Lezhava et al., 2006, PMID 16705247) tested five bioregulators simultaneously – epitalon, livagen, vilon, prostamax and cortagen – on the same aged lymphocyte cultures. All five induced ribosomal gene activation and facultative heterochromatin release. However, the effects were not identical across peptides: epitalon, livagen and prostamax led to decondensation of chromosome 1 pericentromeric structural chromatin, while vilon did not. Epitalon and livagen also altered chromosome 9 heterochromatin, while the other three peptides did not. These differential effects across chromosomes provide the strongest experimental support published to date for the claim that different bioregulator sequences produce different chromatin responses.

The Kolchina 2019 DNA-Binding Motif Study

One of the most methodologically rigorous publications from the programme appeared in Nucleic Acids Research in 2019 (Kolchina, Khavinson et al., vol. 47, pp. 10553-10563). Nucleic Acids Research is a top-tier Western molecular biology journal, and its inclusion of this work represents a level of peer review that most bioregulator publications have not undergone. The study used a systematic computational search to identify structural motifs through which short peptides could bind to double-stranded DNA, providing a theoretical framework for how sequence specificity might operate at the molecular level.

The Italian Stem Cell Collaboration (2020)

A 2020 study published in Molecules (Khavinson, Diomede, Sinjari et al.) was conducted in collaboration with the University of Chieti “G. d’Annunzio” in Italy, marking one of the few instances where a bioregulator compound was tested in a Western laboratory. The study examined epitalon’s effect on neurogenic differentiation in human gingival mesenchymal stem cells and found that AEDG increased the synthesis of neuronal differentiation markers (Nestin, GAP43, beta-Tubulin III and Doublecortin) by 1.6-1.8 times. Molecular modelling identified specific histone binding sites: AEDG was predicted to bind preferentially to H1/3 and H1/6 histones at identified amino acid sequences.

A separate 2020 study (Ashapkin, Khavinson et al., Molecular Biology Reports, PMID 32399807) tested multiple short peptides on ageing human mesenchymal stem cell cultures and found that vesugen (KED) outperformed epitalon (AEDG) in reducing the senescence markers p16 and p21, achieving reductions of 1.82-3.23 fold versus epitalon’s 1.56-2.44 fold. This finding is noteworthy because it suggests quantifiable differences in potency between bioregulators on specific gene targets, consistent with the tissue-specificity hypothesis.

The bottom line: The Lezhava chromatin studies provide the strongest experimental evidence that different bioregulator sequences produce different chromatin effects in aged human cells, while the 2019 Nucleic Acids Research paper and 2020 Italian collaboration bring fragments of the programme’s claims into the orbit of Western peer review.

The Khavinson programme has identified and synthesised over 15 tissue-specific short peptides. The table below lists the major Cytogen (synthetic) bioregulators, their sequences, and their proposed target tissues.

Peptide	Sequence	Length	Target Tissue
Epitalon	Ala-Glu-Asp-Gly (AEDG)	Tetrapeptide	Pineal gland
Pinealon	Glu-Asp-Arg (EDR)	Tripeptide	Brain / CNS
Vilon	Lys-Glu (KE)	Dipeptide	Thymus / immune
Thymogen	Glu-Trp (EW)	Dipeptide	Thymus / immune
Cortagen	Ala-Glu-Asp-Pro (AEDP)	Tetrapeptide	Brain cortex
Cardiogen	Ala-Glu-Asp-Arg (AEDR)	Tetrapeptide	Heart muscle
Vesugen	Lys-Glu-Asp (KED)	Tripeptide	Blood vessels
Livagen	Lys-Glu-Asp-Ala (KEDA)	Tetrapeptide	Liver
Chonluten	Glu-Asp-Gly (EDG)	Tripeptide	Lungs / alveolar
Pancragen	Lys-Glu-Asp-Trp (KEDW)	Tetrapeptide	Pancreas
Bronchogen	Ala-Glu-Asp-Leu (AEDL)	Tetrapeptide	Bronchial tissue
Cartalax	Ala-Glu-Asp (AED)	Tripeptide	Cartilage
Testagen	Lys-Glu-Asp-Gly (KEDG)	Tetrapeptide	Testes

A pattern is visible in the sequences: many share common amino acid building blocks (particularly Ala, Glu and Asp appear across multiple peptides). The tissue specificity is proposed to arise from the precise order and combination of those residues, with each sequence matching different DNA promoter motifs. Whether this degree of specificity can truly be achieved by such short sequences remains one of the unresolved questions in bioregulator research.

Each Cytogen has a corresponding Cytomax (natural extract) product, marketed under separate brand names. Endoluten is the Cytomax pineal product, Vladonix the thymus product, Cerluten the brain product, Chelohart the cardiac product, Ventfort the vascular product, and so on. The Cytogens are synthetic and faster-acting; the Cytomaxes are extracted from young animal tissues and are considered by the programme to have a broader but slower activity profile.

The bottom line: The Khavinson programme has produced at least 15 synthetic tissue-specific peptides, but epitalon is the only one with a substantial international evidence base, and even that evidence originates primarily from one research group.

The longest-duration human data in the bioregulator field comes from a 6-to-8-year non-blinded, non-randomised clinical programme published by Khavinson and Morozov in Neuroendocrinology Letters in 2003. Researchers at the St Petersburg Institute and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences in Kyiv assessed 266 elderly patients (aged 60-80) who received courses of thymalin and epithalamin over the first two to three years, with follow-up continuing for a further three to five years.

The study reported that bioregulator treatment normalised indices across the cardiovascular, endocrine, immune and nervous systems, and that acute respiratory disease incidence fell 2.0-2.4 fold compared with the standard-geriatric-care comparator group. The thymalin-only cohort showed a reported mortality reduction of 2.0-2.1 fold; when thymalin was combined with epithalamin, the reduction was reported at 2.5 fold.

Animal lifespan data from the same programme reported 20-40% lifespan extensions in rodent models, but again from a single laboratory. No independent laboratory has replicated the lifespan extension findings in any model organism.

The bottom line: The 266-patient, 6-to-8-year thymalin-epithalamin mortality study is the most developed human longevity dataset in non-approved peptide research, but its lack of blinding, randomisation and independent replication limits its evidential weight.

Two of the five spoke articles in PeptideGuider’s longevity peptides cluster cover Khavinson bioregulators in depth:

• Epitalon (AEDG tetrapeptide) – the synthetic analogue of epithalamin, targeting the pineal gland. Epitalon is the most studied compound in the bioregulator class and the only one with telomerase-activation data in human cell cultures. Its evidence base, regulatory position and safety profile are covered in full in the dedicated guide.
• Pinealon (EDR tripeptide) – despite its name suggesting a pineal connection, pinealon was derived from brain cortex tissue (not pineal tissue) via the parent drug cortexin. Its evidence base focuses on neuroprotection, oxidative stress reduction and DNA-promoter interaction rather than telomerase or melatonin. The dedicated guide covers its mechanism, evidence and the Huberman Lab REM sleep discussion.

A direct head-to-head comparison of these two compounds is available in our epitalon vs pinealon guide, which examines their structural, mechanistic and evidential differences.

The remaining three spokes in the longevity cluster cover compounds that operate through entirely different biological mechanisms: MOTS-c (AMPK activation), SS-31/elamipretide (cardiolipin stabilisation) and FOXO4-DRI (senolytic apoptosis). None of these are bioregulators and they are not part of the Khavinson research programme.

The bottom line: Of the full bioregulator catalogue, epitalon and pinealon are the two compounds most relevant to the longevity peptide landscape, but they target fundamentally different biological processes.

No Khavinson bioregulator has received regulatory approval from the FDA, EMA, MHRA or TGA for any indication. The tissue-extract preparations (thymalin, epithalamin, cortexin, retinalamin, prostatilen) do not satisfy the 503A bulk drug substance eligibility criteria under 21 U.S.C., as they have no FDA-approved drug component, no USP/NF monograph and are not on the FDA’s bulk substances list.

Epitalon, the most widely discussed synthetic bioregulator, is scheduled for review by the FDA’s Pharmacy Compounding Advisory Committee (PCAC) in July 2026 for an insomnia indication. For the full regulatory context including the RFK-era reclassification and the difference between FDA Category 1 and Category 2 pathways, see the dedicated regulatory guides.

Pinealon is not Category 2, has never been nominated for the 503A Bulks List, and is not scheduled for PCAC review. For how individual countries regulate peptides more broadly, see our guides to peptide legality in the US, the UK and Australia.

The bottom line: Bioregulators are registered pharmaceuticals in Russia but have no regulatory pathway, approval or recognised compounding status in the US, UK, EU or Australia.

The bioregulator field faces several systemic limitations that any informed reader should understand:

Concentration of research. The overwhelming majority of published data originates from one institution (the St Petersburg Institute of Bioregulation and Gerontology) and one research group. Independent replication by Western or international laboratories is extremely limited. This is the single most important caveat in the entire field.

Study design limitations. Most human data are observational or open-label. The landmark longevity study described above was not blinded or randomised. Many animal studies use pretreatment designs (administering the peptide before the insult), which limits translational relevance to ageing, where damage is already present.

Mechanism verification. The DNA-interaction hypothesis is supported by fluorescence labelling, molecular docking and chromatin decondensation studies, but high-resolution structural data (X-ray crystallography or cryo-EM) confirming the proposed peptide-DNA binding events has not been published. The specificity claim, that a tripeptide can reliably target one tissue’s genes while leaving others unaffected, remains unverified at the resolution that modern structural biology demands.

Commercial conflicts. The Khavinson programme has direct commercial ties to the Cytogen, Cytomax and Vitual product lines. Research claims and product marketing are not always clearly separated, which complicates objective evaluation of the evidence.

The bottom line: The bioregulator research programme is scientifically serious and its human data are among the most developed in non-approved longevity peptide research, but the concentration of evidence within one group and the absence of independent replication are fundamental weaknesses.

Are Khavinson bioregulators FDA-approved?

No. No Khavinson bioregulator has been approved by the FDA for any indication. Six preparations (thymalin, epithalamin, cortexin, prostatilen, retinalamin and thymogen) are registered pharmaceuticals in Russia, but this approval does not extend to any Western regulatory jurisdiction. Epitalon is scheduled for PCAC review in July 2026 for a potential insomnia indication under the 503A bulk drug substance pathway.

What is the difference between Cytogens and Cytomaxes?

Cytogens are fully synthetic short peptides (the second generation of Khavinson compounds), made by assembling specific amino acid sequences identified as the active components in earlier tissue extracts. Cytomaxes are the first-generation products, consisting of peptide fractions extracted from young animal organs. Each target tissue has both a Cytogen version (for example, epitalon for the pineal gland) and a Cytomax version (endoluten). The Cytogens are purer, more consistent in composition, and faster-acting, while the Cytomaxes contain a broader but less defined mixture of bioactive components.

How do bioregulators differ from other research peptides?

Most research peptides (such as BPC-157, semaglutide or ipamorelin) are longer chains (10-40+ amino acids) that work by binding to specific cell-surface receptors and triggering intracellular signalling cascades. Bioregulators are ultra-short (2-4 amino acids) and are proposed to work by entering the cell nucleus and interacting directly with DNA and chromatin to modulate gene expression. This is a fundamentally different proposed mechanism, though it remains less well-validated than receptor-mediated peptide pharmacology.

Who was Vladimir Khavinson?

Vladimir Khatskelevich Khavinson (27 November 1946 – 6 January 2024) was a Russian gerontologist, Colonel of Medical Service, and Director of the Saint Petersburg Institute of Bioregulation and Gerontology. He authored or co-authored over 775 scientific publications and 196 patents, introduced gerontology as a clinical specialty in Russia, and served as vice-president of the Gerontological Society of the Russian Academy of Sciences. In 2016, he was awarded the Order of Friendship by President Putin for contributions to healthcare and medical science.

Which bioregulator has the strongest evidence?

Epitalon (AEDG) has the most developed evidence base of any synthetic bioregulator, including telomerase activation in human somatic cells (Khavinson 2003), lifespan extension in multiple rodent models, melatonin restoration in primates, and retinal protection data. It is the only bioregulator with a pending FDA review pathway. However, even epitalon’s evidence is concentrated within the St Petersburg research programme and lacks independent replication of its core claims. See the full epitalon guide for the complete evidence review.

Can bioregulators be taken orally?

The Khavinson programme claims oral bioavailability for these ultra-short peptides, and several Cytogen and Cytomax products are marketed in capsule or sublingual form. The rationale is that at only 2-4 amino acids, these peptides are small enough to be transported intact across the intestinal epithelium by dedicated short-peptide transporters (PEPT1 and PEPT2). However, peer-reviewed pharmacokinetic data confirming oral bioavailability for specific bioregulator sequences is limited, and no head-to-head comparison of oral versus injectable absorption has been published in Western journals.

Has the research programme continued since Khavinson’s death?

Khavinson died on 6 January 2024. The St Petersburg Institute of Bioregulation and Gerontology continues to operate, and several of his long-term collaborators (including Linkova and Kozhevnikova) have continued publishing. The commercial product lines (Cytogen, Cytomax and Vitual brands, produced by Cytomedics) also remain in production and distribution. Whether the programme can sustain its research output without its founder and principal investigator remains an open question.